Peripheral proteinopathy in neurodegenerative diseases.

Peripheral proteinopathy in neurodegenerative diseases.

Publication date: Jan 16, 2025

Proteinopathies in neurology typically refer to pathological changes in proteins associated with neurological diseases, such as the aggregation of amyloid β and Tau in Alzheimer’s disease, α-synuclein in Parkinson’s disease and multiple system atrophy, and TAR DNA-binding protein 43 in amyotrophic lateral sclerosis and frontotemporal dementia. Interestingly, these proteins are also commonly found in peripheral tissues, raising important questions about their roles in neurological disorders. Multiple studies have shown that peripherally derived pathological proteins not only travel to the brain through various routes, aggravating brain pathology, but also contribute significantly to peripheral dysfunction, highlighting their crucial impact on neurological diseases. Investigating how these peripherally derived proteins influence the progression of neurological disorders could open new horizons for achieving early diagnosis and treatment. This review summarizes the distribution, transportation pathways, and pathogenic mechanisms of several neurodegenerative disease-related pathological proteins in the periphery, proposing that targeting these peripheral pathological proteins could be a promising strategy for preventing and managing neurological diseases.

Open Access PDF

Concepts Keywords
Amyloid alpha-Synuclein
Dementia alpha-Synuclein
Early Amyloid beta-Peptides
Neurology Amyloid beta-Peptides
Proteinopathy Amyloid β
Animals
Humans
Neurodegenerative Diseases
Neurodegenerative diseases
Peripheral proteinopathies
Tau
tau Proteins
tau Proteins
TDP-43
α-Synuclein

Semantics

Type Source Name
disease MESH proteinopathy
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH Alzheimer’s disease
disease MESH Parkinson’s disease
disease MESH multiple system atrophy
disease MESH amyotrophic lateral sclerosis
pathway KEGG Amyotrophic lateral sclerosis
disease MESH frontotemporal dementia
disease MESH neurological disorders
drug DRUGBANK Thiocolchicoside
disease MESH sclerosis
pathway REACTOME Reproduction
disease MESH pathogenesis
disease MESH inflammation
pathway REACTOME Metabolism
drug DRUGBANK Amino acids
disease MESH neuroinflammation
disease MESH dysbiosis
disease MESH cancer
disease MESH Neurofibrillary tangles
disease MESH adenocarcinoma
drug DRUGBANK Tretamine
pathway REACTOME Acetylation
disease MESH heart failure
disease MESH bacterial pneumonia
disease MESH sepsis
disease MESH abnormalities
disease MESH oxidative stress
disease MESH sporadic inclusion body myositis
disease MESH polymyositis
drug DRUGBANK Indoleacetic acid
disease MESH myofibrillar myopathies
drug DRUGBANK Ilex paraguariensis leaf
disease MESH death
disease MESH tremor
disease MESH Lewy body dementia
pathway REACTOME Immune System
drug DRUGBANK Hexocyclium
disease MESH clinical progression
drug DRUGBANK Furosemide
disease MESH renal failure
disease MESH amyloid plaques
disease MESH cognitive impairments
drug DRUGBANK Coenzyme M
pathway KEGG Parkinson disease
disease MESH frontotemporal lobar degeneration
pathway KEGG Alzheimer disease
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Trestolone
disease MESH Pneumonia
disease MESH tauopathy
drug DRUGBANK Guanosine
drug DRUGBANK Oxygen
disease MESH fibrosis
disease MESH amyloidosis
pathway REACTOME Antimicrobial peptides
disease MESH infection
drug DRUGBANK Serine
disease MESH TDP 43 proteinopathies
drug DRUGBANK L-Aspartic Acid
disease MESH myopathy
disease MESH arthritis
disease MESH Periodontitis
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK Ranitidine
drug DRUGBANK Sulfasalazine
disease MESH alpha synuclein pathology
disease MESH dementia

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *